Managing HIV may get a bit easier for Europeans. The European Commission have given the green light to Atripla, a pill which combines three powerful drugs.
Atripla combines three existing drugs (efavirenz, tenofovir and emtricitabine). It has come into existence as a result of collaboration between three rival drug companies – Gilead Sciences, Bristol-Myers Squibb and Merck.
The single pill was licensed in the US in July last year – and is now given to half of all patients who are newly diagnosed there.
While the European Commission may have approved Atripla, it’s up to individual countries to make it available.
